EBE Position Paper: "A Risk-Based Approach to Identity Sampling of Biological Drug Substances"
Good Manufacturing Practices require that the identity of materials received for use in the manufacturing of drug products is confirmed. However, the direct sampling of primary containers of biological drug (active) substances at the biological drug product manufacturing site, after thaw can expose the biological drug substance to risks. The use of a representative sample